. Author manuscript; available in PMC: 2014 Apr 1.

Published in final edited form as: Nat Rev Clin Oncol. 2013 Feb 5;10(4):211–224. doi: 10.1038/nrclinonc.2013.5

Table 2.

Comparison and contrast of the two frontline adjuvant phase III trials in ovarian cancer patients, which studied bevacizumab.

Study design parameter	GOG 218	ICON 7
n	1,873	1,528
Disease characteristics	Previously untreated EOC, PPC, or FTC	Previously untreated EOC, PPC, or FTC
FIGO stage	III–IV	High risk I–IIA, IIB–IV
Arms	Chemotherapy vs chemotherapy plus bevacizumab vs chemotherapy plus bevacizumab → bevacizumab	Chemotherapy vs chemotherapy plus bevacizumab → bevacizumab
Placebo controlled	Yes	No
Bevacizumab dosage	15 mg/kg every 21 days	7.5 mg/kg every 21 days
Duration of maintenance therapy	16 cycles (~11 months)	12 cycles (~8 months)
Primary end point	PFS^*	PFS
Secondary end points	OS, quality of life, correlative laboratory studies	OS, RR, safety, quality of life, economics
Enrollment period	October 2005 to June 2009	December 2006 to February 2009
Current status	Completed; published December 2011⁴⁵	Completed; published December 2011⁴⁶

Abbreviations: EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics; FTC, fallopian tube cancer; GOG, Gynecologic Oncology Group; OS, overall survival; PFS, progression-free survival; PPC, primary peritoneal cancer; RR, response rate.

Originally designated as OS but modified to PFS during the trial.